Mertz D P, Engelstätter R
Fortschr Med. 1982 Nov 11;100(42):1978-82.
The influence of Ebrantil on serum electrolytes, lipids, and lipoproteins was studied in 8 normotensives and 10 hypertensives. For this purpose, Ebrantil sustained-release capsules were administered after a 7-10 day diet phase concomitantly with the diet for a period of 2 weeks. Before and after the diet phase, as well as subsequent to the treatment period, laboratory parameters were determined in fasting blood. The serum levels of sodium, potassium, calcium, and magnesium were identical at all measuring times. The concentrations of triglycerides, phospholipids, total cholesterol, VLDL-, LDL-, HDL-cholesterol, and of the apolipoproteins AI, AII and B measured in all patients at the end of the treatment period deviated only slightly from those determined in the diet phase. The mean value for the arteriosclerosis index LDL/HDL decreases significantly during treatment. The results reveal that Ebrantil has no negative influence on electrolyte balance and lipometabolism.
在8名血压正常者和10名高血压患者中研究了依那普利对血清电解质、脂质和脂蛋白的影响。为此，在为期7 - 10天的饮食阶段后，给予依那普利缓释胶囊，并与饮食同时服用2周。在饮食阶段前后以及治疗期之后，于空腹血中测定实验室参数。在所有测量时间，钠、钾、钙和镁的血清水平均相同。在治疗期末，所有患者测得的甘油三酯、磷脂、总胆固醇、极低密度脂蛋白胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇以及载脂蛋白AI、AII和B的浓度与饮食阶段所测值相比仅有轻微偏差。治疗期间动脉硬化指数低密度脂蛋白/高密度脂蛋白的平均值显著降低。结果显示，依那普利对电解质平衡和脂质代谢无负面影响。
